DOCSLIB.ORG

Evolving Drug Therapies for Chronic Hepatitis C Immunomodulation and Beyond

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evolving Drug Therapies for Chronic Hepatitis C Immunomodulation and Beyond Evolving drug therapies for chronic hepatitis C Immunomodulation and beyond Jilling Bergmann stellingen // PROEfSCHRIfT Stellingen behorende bij het proefschrift Evolving drug therapies for chronic hepatitis C Immunomodulation and beyond Jilling Bergmann, 23 november 2011 1 Behandeling met een hoge dosis peginterferon alfa in HCV geïnfecteerde patiënten is over het algemeen veilig maar leidt niet tot verbetering van de behandeluitkomst in vergelijking met de standaard dosis peginterferon. (dit proefschrift) 2 Continue subcutane toediening van standaard interferon alfa in combinatie met ribavirine kan leiden tot een blijvende virologische repons in eerdere peginterferon non-responders. (dit proefschrift) 3 Endogene inductie van interferon alfa na toediening van een orale toll-like receptor agonist kan leiden tot een significante HCV RNA daling. (dit proefschrift) 4 Behandeling met narlaprevir (een NS3 proteaseremmer) gedurende 7 dagen leidt tot een meer dan 4 log10 HCV RNA daling in zowel naïeve patiënten als eerdere non-responders. (dit proefschrift) 5 Toevoeging van ritonavir leidt tot een verbetering van het farmacokinetisch profiel van narlaprevir door remming van cytochroom P450-3A4 waardoor tweemaal daags doseringen mogelijk zijn in plaats van driemaal daags. (dit proefschrift) 6 Over 10 jaar is chronische hepatitis C mogelijk een zeldzame aandoening in de Westerse wereld mits we bereid zijn om ruwweg x 75.000,- voor een antivirale behandeling neer te tellen. 7 Wetenschap lost nooit problemen op zonder 10 nieuwe problemen te creëren. (George Bernard Shaw) 8 Niemand heeft bezwaar tegen evidence-based medische richtlijnen zolang er maar te allen tijde van afgeweken kan worden. 9 De mens gebruikt de eerste helft van zijn leven om zijn gezondheid te ruïneren, terwijl hij de tweede helft op zoek gaat naar genezing. (Leonardo da Vinci) 10 Het beste argument tegen democratie is een conversatie van vijf minuten met een gemiddelde stemgerechtigde. (Winston Churchill) 11 Ik weet niets van muziek, in mijn vakgebied is dat ook niet nodig. (Elvis Presley) Later in the evenin’ As you lie awake in bed With the echoes from the amplifiers Ringin’ in your head You smoke the day’s last cigarette Rememberin’ what she said Here I am, on the road again There I am, up on the stage Here I go, playin’ star again There I go, turn the page (Turn the page, Bob Seger, 1972) Voor Francesca, Sara en Maurits Evolving drug therapies for chronic hepatitis C Immunomodulation and beyond Jilling Bergmann Colofon © 2011 Jilling Bergmann, the Netherlands ISBN 978-90-818186-0-5 Graphic design studio Tineke Wieringa bno, Haren Printing Het Grafisch Huis, Groningen Financial support for design and printing was kindly given by the Department of Gastroenterology and Hepatology of the Erasmus University Medical Center Rotterdam, Erasmus University Rotterdam, Nederlandse Vereniging voor Hepatologie, PRA International, Gilead, MSD, Janssen-Cilag, Roche, Zambon, Ferring, Vifor, Tramedico, Abbott, Glaxosmithkline and studio Tineke Wieringa. All rights reserved. No part of this thesis may be reproduced or transmitted in any for or by any means, without prior written submission of the author. The work presented in this thesis was conducted at the Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, the Netherlands. Evolving drug therapies for chronic hepatitis C Immunomodulation and beyond Therapeutische ontwikkelingen voor chronische hepatitis C Immunomodulatie en meer Proefschrift ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof.dr. H.G. Schmidt en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op woensdag 23 november 2011 om 13.30 uur door Jilling Frederik Bergmann geboren te Groningen Promotiecommissie Promotor Prof.dr. H.L.A. Janssen Overige leden Prof.dr. C.A.B. Boucher Prof.dr. M. Peppelenbosch Dr. H.W. Reesink Copromotor Dr. R.J. de Knegt ConTEnTS // 7 Contents Chapter 1 8 General introduction Chapter 2 16 What is on the horizon for treatment of chronic hepatitis C? Chapter 3 34 Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon alfa-2b in chronic hepatitis C non-responders Chapter 4 48 Continuous interferon alfa-2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients Chapter 5 63 Viral kinetics and immune activation during continuous subcutaneous administration of high-dose interferon alfa-2b in treatment-experienced chronic hepatitis C patients Chapter 6 76 Randomized clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV Chapter 7 92 Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via TLR7 Chapter 8 106 Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor Chapter 9 120 Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients Summary and discussion 136 Samenvatting en discussie 144 List of publications 153 PhD portfolio summary 154 Dankwoord 156 Curriculum Vitae 159 Chapter 1 General introduction GEnERal inTRoduction // 9 Introduction Chronic hepatitis C infection is a major health problem and a leading cause of chronic liver disease. The hepatitis C virus was discovered in 1989 (1, 2). The virus is a small, enveloped, single-stranded, positive sense Rna virus and is a member of the hepacivirus genus in the family Flaviridae (3). Six major genotypes have been identified with several subtypes within each genotype (4). Viral replication occurs predominantly within hepatocytes in the liver but there is some evidence that it might also replicate outside the liver, in peripheral blood mononuclear cells, in lymphoid cells and in neurons (5, 6). Chronic hepatitis C infection can cause cirrhosis, digestive hemorrhage, liver failure and liver cancer. Transmission of the hepatitis C virus (HCV) is mainly related to parenteral contact with blood and blood products. Blood transfusions and the use of shared, nonsterilized needles and syringes have been the main causes of the spread of HCV. after the introduction of routine blood screening for HCV antibody (1992 in most countries), transfusion-related hepatitis C virtually disappeared (7, 8). at present in the developed world, injection drug use is the most common risk factor. Body piercing, tattoos and sharing tooth brushes or razors with an infected person have also been described as risk factors for transmission (9, 10). High-risk sexual behavior of HiV-infected gay men might be a risk factor as well, whereas sexual transmission of HCV between monogamous partners is uncommon (11, 12). There is a small risk of transmission during delivery of a child from an infected mother (13). an estimated 180 million people worldwide are infected with hepatitis C (14). The prevalence of chronic hepatitis C in Europe and north america is 1.0 to 1.7 percent. The prevalence is higher in Southern Europe, in asia and in Egypt. in the netherlands approximately 0.1 to 0.4% of the population is chronically infected (15). Hepatitis C is most prevalent among hemophiliacs who received plasma derived clotting factor concentrates before 1987 (after which time viral inactivation procedures were implemented), among intravenous drug users and among prison inmates (16). acute HCV infection is often subclinical and only 20-40% of the patients experience symptoms such as jaundice, nausea, abdominal pain or general unwellness (17). acute icteric patients are more likely to spontaneously clear the infection than patients with a subclinical infection (18). The virus persists in 60-85% of infected patients, leading to chronic inflammation of the liver. During the early phase of chronic infection, patients are often asymptomatic or experience aspecific symptoms such as fa- tigue. it may take years or even decades before patients discover that they have chronic hepatitis C infection. Patients may be identified when routine blood tests show elevated liver enzyme values or if there are known risk factors. a small proportion of infected patients (1-2%) develop extrahepatic manifestations of hepatitis C, such as porphyria cutanea tarda, glomerulonephritis, or vasculitis due to cryoglobulinemia (19, 20). Chronic hepatitis C leads to slow but progressive increasing degrees of fibrosis (21). Fibrosis is the de- leterious but variable consequence of chronic inflammation. it is characterized by the deposition of an extracellular matrix component, leading to the distortion of the hepatic architecture with impairment of liver microcirculation and liver cell functions. Usually, HCV infection is lethal only when it leads to cirrhosis, the last stage of liver fibrosis. The rate of fibrosis progression is affected by some host-related characteristics such as the duration of the infection, alcohol abuse and factors like co-infection with hepatitis B virus (HBV) or HiV. Shortly after the discovery of the hepatitis C virus, interferon alfa was approved as anti-HCV treatment. although the mechanism of action of interferon has not been fully clarified, it has been shown that interferon has both a direct antiviral effect as well as important interactions with the adaptive and 10 // GEnERal inTRoduction innate immune reponses (22). Clearance of hepatitis C virus is associated
Load more

Recommended publications
  • COVID-19 Drugs: Are There Any That Work? 24 August 2020, by from Mayo Clinic News Network, Mayo Clinic News Network
    COVID-19 drugs: Are there any that work? 24 August 2020, by From Mayo Clinic News Network, Mayo Clinic News Network dysfunction and lung injury from inflammation. A recent study found it reduced deaths by about 30% for people on ventilators and by about 20% for people who needed supplemental oxygen. The U.S. National Institutes of Health has recommended this drug for people hospitalized with COVID-19 who are on mechanical ventilators or need supplemental oxygen. Other corticosteroids, such as prednisone, methylprednisolone or hydrocortisone, may be used if dexamethasone isn't available. However, their effectiveness isn't yet known. Dexamethasone and other corticosteroids may be harmful if given for less severe COVID-19 infection. Credit: Unsplash/CC0 Public Domain Anti-inflammatory therapy. Researchers study many anti-inflammatory drugs to treat or prevent dysfunction of several organs and lung injury from infection-associated inflammation. Question: I've heard several drugs mentioned as possible treatments for COVID-19. What are they Immune-based therapy. Researchers are studying and how do they work? the use of a type of immune-based therapy called convalescent plasma. Convalescent plasma is Answer: Although there is no product approved by blood donated by people who've recovered from the Food and Drug Administration to treat COVID-19. It is used to treat people who are coronavirus disease 2019 (COVID-19), many seriously ill with the disease. medications are being tested. Drugs being studied that have uncertain One investigational drug called remdesivir has effectiveness. Researchers are studying been authorized by the FDA for emergency use amlodipine, ivermectin, losartan and famotidine.
    [Show full text]
  • COVID-19: Predicting Inhibition of the Main Protease and Therapeutic Intracellular Accumulation and Plasma and Lung Concentratio
    COVID-19: predicting inhibition of the main protease and therapeutic intracellular accumulation and plasma and lung concentrations of repurposed inhibitors Clifford Fong To cite this version: Clifford Fong. COVID-19: predicting inhibition of the main protease and therapeutic intracellu- lar accumulation and plasma and lung concentrations of repurposed inhibitors. [Research Report] Eigenenergy. 2020. hal-02917312 HAL Id: hal-02917312 https://hal.archives-ouvertes.fr/hal-02917312 Submitted on 20 Aug 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. COVID-19: predicting inhibition of the main protease and therapeutic intracellular accumulation and plasma and lung concentrations of repurposed inhibitors Clifford W. Fong Eigenenergy, Adelaide, South Australia, Australia. Email: [email protected] Keywords: COVID-2019 or SARS-CoV-2; SARS-CoV; MERS; 3C-like protease, or 3CLpro, pro or M ; inhibition; IC50, EC50, EC90, host cell membrane transport, AUC, Cmax, linear free energy relationships, HOMO-LUMO; quantum mechanics; Abbreviations: Structure
    [Show full text]
  • Antivirals Against the Chikungunya Virus
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 June 2021 Review Antivirals against the Chikungunya Virus Verena Battisti 1, Ernst Urban 2 and Thierry Langer 3,* 1 University of Vienna, Department of Pharmaceutical Sciences, Pharmaceutical Chemistry Division, A-1090 Vienna, Austria; [email protected] 2 University of Vienna, Department of Pharmaceutical Sciences, Pharmaceutical Chemistry Division, A-1090 Vienna, Austria; [email protected] 3 University of Vienna, Department of Pharmaceutical Sciences, Pharmaceutical Chemistry Division, A-1090 Vienna, Austria; * Correspondence: [email protected] Abstract: Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that has re-emerged in recent decades, causing large-scale epidemics in many parts of the world. CHIKV infection leads to a febrile disease known as chikungunya fever (CHIKF), which is characterised by severe joint pain and myalgia. As many patients develop a painful chronic stage and neither antiviral drugs nor vac- cines are available, the development of a potent CHIKV inhibiting drug is crucial for CHIKF treat- ment. A comprehensive summary of current antiviral research and development of small-molecule inhibitor against CHIKV is presented in this review. We highlight different approaches used for the identification of such compounds and further discuss the identification and application of promis- ing viral and host targets. Keywords: Chikungunya virus ; alphavirus; antiviral therapy; direct-acting antivirals; host-directed antivirals; in silico screening; in vivo validation, antiviral drug development 1. Introduction Chikungunya virus (CHIKV) is a mosquito-borne alphavirus and belongs to the Togaviridae family. The virus was first isolated from a febrile patient in 1952/53 in the Makonde plateau (Tanzania) and has been named after the Makonde word for “that which bends you up”, describing the characteristic posture of patients suffering severe joint pains due to the CHIKV infection [1].
    [Show full text]
  • What's in the Pipeline: New HIV Drugs, Vaccines, Microbicides, HCV And
    What’s in the Pipeline: New HIV Drugs, Vaccines, Microbicides, HCV and TB Treatments in Clinical Trials by Rob Camp, Richard Jefferys, Tracy Swan & Javid Syed edited by Mark Harrington & Bob Huff Treatment Action Group New York, NY, USA July 2005 e thymidine • BI-201 • Racivir (PSI 5004) • TMC-278 • Diarylpyrimidine (DAPY) • 640385 • Reverset (D-D4FC) • JTK-303 • UK-427 (maraviroc) • Amdoxovir • AMD-070 • Vicriviroc LIPO-5 • GTU-Multi-HIV • pHIS-HIV-B • rFPV-HIV-B • ADMVA • GSK Protein HIV Vaccine TBC-M335 (MVA) • TBC-F357 (FPV) • TBC-F349 (FPV) • LIPO-4T (LPHIV-1) • LFn-p24 • H G • Oligomeric gp140/MF59 • VRC-HIVDNA-009-00-VP • PolyEnv1 • ISS P-001 • EP HIV- • BufferGel • Lactin-V • Protected Lactobacilli in combination with BZK • Tenofovir/PMPA G ulose acetate/CAP) • Lime Juice • TMC120 • UC-781 • VivaGel (SPL7013 gel) • ALVAC Ad5 • Autologous dendritic cells pulsed w/ALVAC • Autologous dendritic cell HIV vaccination x • Tat vaccine • GTU-nef DNA vaccine • Interleukin-2 (IL-2) • HE2000 • Pegasys (peginter L-4/IL-13 trap • Serostim • Tucaresol • MDX-010 anti-CTLA4 antibody • Cyclosporine A • 496 • HGTV43 • M87o • Vertex • VX-950 • Idenix • Valopicitabine (NM283) • JTK-003 mplant • Albuferon • Celgosivir (MBI-3253) • IC41 • INN0101 • Tarvicin • ANA971 (oral) floxacin, Tequin • J, TMC207 (ex R207910) • LL-3858 • M, moxifloxacin, Avelox • PA-824 Acknowledgements. Thanks to our intrepid editors, Bob Huff, copy-editor Andrea Dailey, and proof-reader Jen Curry, to awesome layout expert Lei Chou, to webmaster Joel Beard, to Joe McConnell for handling administrative matters related to the report, and most of all to the board and supporters of TAG for making our work possible.
    [Show full text]
  • Differences in Clinical Outcomes Among Hepatitis C Genotype 1
    Clinical and Experimental Gastroenterology Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis Eric Druyts1 Background: With the development of new direct acting antiviral (DAA) therapy for hepatitis Edward J Mills1,2 C, the backbone peginterferon alpha used may be of importance in maximizing treatment Jean Nachega3 outcomes. To this end, the rates of sustained virologic response (SVR), relapse, and treatment Christopher O’Regan4 discontinuation among hepatitis C genotype 1-infected patients given peginterferon alpha-2a Curtis L Cooper5 plus ribavirin or peginterferon alpha-2b plus ribavirin were determined using a meta-analysis. Methods: Randomized trials examining peginterferon alpha-2a or peginterferon alpha-2b co- 1Faculty of Health Sciences, University administered with ribavirin for 48 weeks were included. Data were extracted on SVR, relapse, of Ottawa, Ottawa, ON, Canada; For personal use only. 2Department of Clinical Epidemiology and treatment discontinuations for treatment-naïve and treatment-experienced patients. Pooled and Biostatistics, McMaster University, proportions using fixed and random effects meta-analysis were calculated. Hamilton, ON, Canada; 3Centre for Infectious Diseases, Stellenbosch Results: Twenty-six trials provided data on patients treated with peginterferon alpha-2a plus University, Stellenbosch,
    [Show full text]
  • Existing Drugs Considered As Promising in COVID-19 Therapy
    International Journal of Molecular Sciences Review Existing Drugs Considered as Promising in COVID-19 Therapy Edyta Janik 1 , Marcin Niemcewicz 1 , Marcin Podogrocki 1, Joanna Saluk-Bijak 2 and Michal Bijak 1,* 1 Biohazard Prevention Centre, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland; [email protected] (E.J.); [email protected] (M.N.); [email protected] (M.P.) 2 Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland; [email protected] * Correspondence: [email protected]; Tel./Fax: +48-42-635-43-36 Abstract: COVID-19 is a respiratory disease caused by newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease at first was identified in the city of Wuhan, China in December 2019. Being a human infectious disease, it causes high fever, cough, breathing problems. In some cases it can be fatal, especially in people with comorbidities like heart or kidney problems and diabetes. The current COVID-19 treatment is based on symptomatic therapy, so finding an appropriate drug against COVID-19 remains an immediate and crucial target for the global scientific community. Two main processes are thought to be responsible for the COVID-19 pathogenesis. In the early stages of infection, disease is determined mainly by virus replication. In the later stages of infection, by an excessive immune/inflammatory response, leading to tissue damage. Therefore, the main treatment options are antiviral and immunomodulatory/anti-inflammatory agents.
    [Show full text]
  • Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: a Century-Long Story
    Review Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story Rand Naffouje 1, Punita Grover 1, Hongyang Yu 2,3, Arun Sendilnathan 1, Kara Wolfe 1,4, Nazanin Majd 5, Eric P. Smith 6, Koh Takeuchi 7, Toshiya Senda 2,3, Satoshi Kofuji 8 and Atsuo T. Sasaki 1,4,9,10,* 1 Division of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA; [email protected] (P.G.); [email protected] (A.S.); [email protected] (K.W.); [email protected] (A.T.S.) 2 Structural Biology Research Center, Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tokyo 135-0063, Japan; [email protected] (H.Y.); [email protected] (T.S.) 3 Department of Accelerator Science, School of High Energy Accelerator Science, SOKENDAI (the Graduate University for Advanced Studies), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan 4 Department of Cancer Biology, University of Cincinnati College of Medicine, OH 45267, USA 5 Department of Neuro-oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; [email protected] 6 Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA; [email protected] 7 Molecular Profiling Research Center for Drug Discovery, National Institute of Advanced Science and Technology, 2-3-26 Aomi, Koto, Tokyo 135-0063, Japan; [email protected] 8 Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan; [email protected] 9 Department of Neurosurgery, Brain Tumor Center at UC Gardner Neuroscience Institute, Cincinnati, OH 45267, USA 10 Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata 997-0052, Japan * Correspondence: [email protected] Received: 9 August 2019; Accepted: 2 September 2019; Published: 11 September 2019 Abstract: The purine nucleotides ATP and GTP are essential precursors to DNA and RNA synthesis and fundamental for energy metabolism.
    [Show full text]
  • 24 March 2011 (24.03.2011) W O 201 1 /03 523 1 a 1
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau „ (10) International Publication Number (43) International Publication Date 24 March 2011 (24.03.2011) W O 201 1 /03 523 1 A 1 (51) International Patent Classification: (74) Agents: WARD, John et al.; Gilead Sciences, Inc., 333 C07D 487/04 (2006.01) Lakeside Drive, Foster City, CA 94404 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US20 10/049471 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (22) International Filing Date: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, 20 September 2010 (20.09.2010) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Langi English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (30) Priority Data: NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, 61/244,297 2 1 September 2009 (21 .09.2009) US SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant (for all designated States except US): GILEAD SCIENCES, INC. [US/US]; 333 Lakeside (84) Designated States (unless otherwise indicated, for every Drive, Foster City, CA 94404 (US).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen Et Al
    US 2008O161324A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen et al. (43) Pub. Date: Jul. 3, 2008 (54) COMPOSITIONS AND METHODS FOR Publication Classification TREATMENT OF VRAL DISEASES (51) Int. Cl. (76) Inventors: Lisa M. Johansen, Belmont, MA A63/495 (2006.01) (US); Christopher M. Owens, A63L/35 (2006.01) Cambridge, MA (US); Christina CI2O I/68 (2006.01) Mawhinney, Jamaica Plain, MA A63L/404 (2006.01) (US); Todd W. Chappell, Boston, A63L/35 (2006.01) MA (US); Alexander T. Brown, A63/4965 (2006.01) Watertown, MA (US); Michael G. A6II 3L/21 (2006.01) Frank, Boston, MA (US); Ralf A6IP3L/20 (2006.01) Altmeyer, Singapore (SG) (52) U.S. Cl. ........ 514/255.03: 514/647; 435/6: 514/415; Correspondence Address: 514/460, 514/275: 514/529 CLARK & ELBNG LLP 101 FEDERAL STREET BOSTON, MA 02110 (57) ABSTRACT (21) Appl. No.: 11/900,893 The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain (22) Filed: Sep. 13, 2007 embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particu Related U.S. Application Data lar embodiments, the viral disease is viral hepatitis (e.g., (60) Provisional application No. 60/844,463, filed on Sep. hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). 14, 2006, provisional application No. 60/874.061, Also featured are screening methods for identification of filed on Dec. 11, 2006. novel compounds that may be used to treat a viral disease.
    [Show full text]
  • A SARS-Cov-2 Protein Interaction Map Reveals Targets for Drug Repurposing
    Article A SARS-CoV-2 protein interaction map reveals targets for drug repurposing https://doi.org/10.1038/s41586-020-2286-9 A list of authors and affiliations appears at the end of the paper Received: 23 March 2020 Accepted: 22 April 2020 A newly described coronavirus named severe acute respiratory syndrome Published online: 30 April 2020 coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than Check for updates 160,000 individuals and caused worldwide social and economic disruption1,2. There are no antiviral drugs with proven clinical efcacy for the treatment of COVID-19, nor are there any vaccines that prevent infection with SARS-CoV-2, and eforts to develop drugs and vaccines are hampered by the limited knowledge of the molecular details of how SARS-CoV-2 infects cells. Here we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identifed the human proteins that physically associated with each of the SARS-CoV-2 proteins using afnity-purifcation mass spectrometry, identifying 332 high-confdence protein–protein interactions between SARS-CoV-2 and human proteins. Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (of which, 29 drugs are approved by the US Food and Drug Administration, 12 are in clinical trials and 28 are preclinical compounds). We screened a subset of these in multiple viral assays and found two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the sigma-1 and sigma-2 receptors.
    [Show full text]
  • Technology Report No 47
    Interferon-based Therapies for Technology Chronic Hepatitis C Virus Infection: An Assessment of Report Clinical Outcomes Issue 47 May 2004 i Publications can be requested from: CCOHTA 600-865 Carling Avenue Ottawa ON Canada K1S 5S8 Tel. (613) 226-2553 Fax. (613) 226-5392 Email: [email protected] or download from CCOHTA’s web site: http://www.ccohta.ca Cite as: Husereau D, Bassett K, Koretz R. Inteferon-based therapies for chronic hepatitis C virus infection: an assessment of clinical outcomes.Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2004. Technology report no 47. Reproduction of this document for non-commercial purposes is permitted provided appropriate credit is given to CCOHTA. CCOHTA is a non-profit organization funded by the federal, provincial and territorial governments. Legal Deposit – 2004 National Library of Canada ISBN: 1-894978-28-5 (print) ISBN: 1-894978-29-3 (electronic version) PUBLICATIONS MAIL AGREEMENT NO: 40026386 RETURN UNDELIVERABLE CANADIAN ADDRESSES TO CANADIAN COORDINATING OFFICE FOR HEALTH TECHNOLOGY ASSESSMENT 600-865 CARLING AVENUE OTTAWA ON K1S 5S8 ii Canadian Coordinating Office for Health Technology Assessment Inteferon-based Therapies for Chronic Hepatitis C Virus Infection: An Assessment of Clinical Outcomes Donald Husereau BScPharm MSc1 Ken Bassett MD PhD2 Ronald Koretz MD3 May 2004 1 Canadian Coordinating Office for Health Technology Assessment (CCOHTA), Ottawa ON 2 Centre for Health Services and Policy Research, Vancouver BC 3 Olive View UCLA Medical Centre, Sylmar, California
    [Show full text]
  • The IMPDH Inhibitor Merimepodib Suppresses SARS-Cov-2 Replication in Vitro
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.07.028589; this version posted April 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro. Natalya Bukreyeva1, Emily K. Mantlo1, Rachel A. Sattler1, Cheng Huang1, Slobodan Paessler1 and Jerry Zeldis2 1Department of Pathology, University of Texas Medical Branch 2ViralClear, a subsidiary of BioSig, Inc. Abstract: The ongoing COVID-19 pandemic continues to pose a major public health burden around the world. The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected over one million people worldwide as of April, 2020, and has led to the deaths of nearly 300,000 people. No approved vaccines or treatments in the USA currently exist for COVID-19, so there is an urgent need to develop effective countermeasures. The IMPDH inhibitor merimepodib (MMPD) is an investigational antiviral drug that acts as a noncompetitive inhibitor of IMPDH. It has been demonstrated to suppress replication of a variety of emerging RNA viruses. We report here that MMPD suppresses SARS-CoV-2 replication in vitro. After overnight pretreatment of Vero cells with 10 μM of MMPD, viral titers were reduced by 4 logs of magnitude, while pretreatment for 4 hours resulted in a 3-log drop. The effect is dose-dependent, and concentrations as low as 3.3 μM significantly reduced viral titers when the cells were pretreated prior to infection.
    [Show full text]